IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) has received a patent from the United States Patent and Trademark Office entitled, “Film dosage form with extended release mucoadhesive particles.”
The patent covers the design and manufacturing of topical oral films for the local or topical treatment of diseases of the oral mucosa using mucoadhesive particles. The technology is intended to provide sustained release of an active agent to a target area of the oral cavity and is useful for the topical treatment of oral diseases and conditions such as gingivitis, buccal ulcers, canker sores, Sjogren’s syndrome, oral mucositis and Behcet’s disease.
IntelGenx’s topical oral films technology facilitates the controlled release of an active agent to the buccal cavity and its transport through the oral mucosa, while avoiding the discomfort often associated with conventional long lasting mucoadhesive films or tablets.
“This novel patented proprietary technology offers an easy to use and effective delivery system for the treatment of a variety of oral diseases,” Horst Zerbe, CEO, said in a statement.
“We are confident that IntelGenx’s expanding intellectual property estate, including this newly issued patent, will provide our products with long-term market exclusivity,” he added. “This is particularly important as industry awareness and acceptance of our VersaFilm oral film technologies and manufacturing techniques continues to grow.”
With the issuance of this new patent, IntelGenx intends to seek potential commercialization partners for topical oral films in the U.S.
